Solvonis Therapeutics plc
SVNS.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £2,371 | £598 | £14,399 | £23,037 |
| - Cash | £757 | £155 | £1,640 | £598 |
| + Debt | £0 | £34 | £22 | £950 |
| Enterprise Value | £1,614 | £477 | £12,781 | £23,389 |
| Revenue | £0 | £587 | £542 | £219 |
| % Growth | -100% | 8.3% | 147.5% | – |
| Gross Profit | £0 | -£134 | -£51 | £55 |
| % Margin | – | -22.8% | -9.4% | 25.1% |
| EBITDA | -£1,383 | -£2,938 | -£2,588 | -£900 |
| % Margin | – | -500.5% | -477.5% | -411% |
| Net Income | -£1,590 | -£3,120 | -£2,705 | -£954 |
| % Margin | – | -531.5% | -499.1% | -435.6% |
| EPS Diluted | -0.001 | -0.03 | -0.026 | -0.009 |
| % Growth | 96% | -14.9% | -183.7% | – |
| Operating Cash Flow | -£1,130 | -£1,238 | -£2,360 | -£254 |
| Capital Expenditures | -£4 | -£232 | -£718 | -£1 |
| Free Cash Flow | -£1,134 | -£1,470 | -£3,078 | -£255 |